IP Library Granted Patent US 12,508,237
Granted Patent B2
US 12,508,237 · App. 17/790,132 · Granted Dec 30, 2025

Pharmaceutical composition comprising 4-hexylresorcinol as active ingredient for prevention or treatment of bone disease

Inventors: Je-Yong Choi (Daegu, KR); Xiangguo Che (Daegu, KR); Hyun-Ju Kim (Daegu, KR); Dong-Kyo Lee (Changwon-si, KR); Seong-Gon Kim (Seoul, KR); Xian Jin (Daegu, KR)
Assignees: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION; GANGNEUNG-WONJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP
A61K31/05A61K9/06A61K47/44A61P19/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,237
App. No.
17/790,132
Granted
Dec 30, 2025
Kind
B2
Abstract

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

Claims (4)

1 . A method of simultaneously treating osteoporosis and reducing abdominal fat accumulation in a subject in need thereof, comprising:

topically applying an effective amount of a pharmaceutical ointment composition comprising about 2% by weight 4-hexylresorcinol (4-HR) in lanolin oil to a dorsal skin are of the subject,

wherein the 4-hexylresorcinol (4-HR) decreases a level of CTX in blood, increases a level of ALP, promotes differentiation of osteoblasts, and suppresses differentiation of osteoclasts, and

wherein said applying increases bone volume, bone density, and bone thickness, and reduces abdominal fat accumulation in the subject.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2026
From: CELLGUARDIAN CO.,LTD
To: CELLGUARDIAN CO., LTD.
Reel/Frame 075241/0490 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2026
From: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION; KNU-INDUSTRY COOPERATION FOUNDATION
To: CELLGUARDIAN CO.,LTD
Reel/Frame 074844/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2026
From: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION; GANGNEUNG-WONJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP
To: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION; KNU-INDUSTRY COOPERATION FOUNDATION
Reel/Frame 074546/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2022
From: CHOI, JE-YONG; CHE, XIANGGUO; KIM, HYUN-JU; LEE, DONG-KYO; KIM, SEONG-GON; JIN, XIAN
To: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION; GANGNEUNG-WONJU NATIONAL UNIVERSITY INDUSTRY ACADEMY COOPERATION GROUP
Reel/Frame 060361/0464 →
Priority Claims (2)
KR 10-2019-0178187 · Dec 30, 2019 · national
KR 10-2020-0154564 · Nov 18, 2020 · national
Continuity (1)
Related Publication 20230049524A1 · Feb 16, 2023
References Cited (18)
US 20060120975A1 · Scherl et al. · 2006 [cited by applicant]
US 20080286377A1 · Healey et al. · 2008 [cited by applicant]
US 20130171219A1 · Johnson · 2013 [cited by examiner]
US 20190224266A1 · Lin-Shiau · 2019 [cited by examiner]
KR 1020100066675A · 2010 [cited by applicant]
KR 1020110050308A · 2011 [cited by applicant]
KR 1020110135168A · 2011 [cited by applicant]
KR 1020160028824A · 2016 [cited by applicant]
KR 1754155B1 · 2017 [cited by examiner]
KR 102056463B1 · 2019 [cited by applicant]
EFSA ANS Panel (EFSA Journal 12(4):3643, 35 pp. 2014) (Year: 2014). [cited by examiner]
Derwent Accession No. 2017-48070A (English summary of Geun et al (KR 1754155 B1, 2017)). (Year: 2017). [cited by examiner]
Siu et al (Evidence Based Complementary and Alternative Medicine 2015:905270 (10 pages), 2015) (Year: 2015). [cited by examiner]
International Search Report for PCT/KR2020/019227 mailed Jun. 9, 2021 from Korean Intellectual Property Office. [cited by applicant]
Professor R. Walker, “4-HEXYLRESORCINOL”, WHO Food Additive Series 35, 835, Dec. 21, 2019. [cited by applicant]
Korea Association of Colleges of Pharmacy, Pharmaceutical Sciences Division “pharmaceutical science”. [cited by applicant]
Ji-Young Song et al., “Porcine Bone Incorporated With 4-Hexylresorcinol Increases New Bone Formation by Suppression of the Nuclear Factor Kappa B Signaling Pathway”, Journal of Craniofacial Surgery, Oct. 2018 , 29(7): p… [cited by applicant]
Michael McClung, “Role of RANKL inhibition in osteoporosis”, Arthritis Research & Therapy, 2007, 9(Suppl 1):S3 (doi:10.1186/ar2167). [cited by applicant]